Population pharmacokinetics of arbekacin in burn patients

The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population–PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospective...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of clinical pharmacology Vol. 64; no. 6; pp. 599 - 603
Main Authors Kim, Jong Hyun, Lah, Hyon-oh, Yim, Dong-Seok
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer-Verlag 01.06.2008
Springer
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The aim of this study was to estimate the pharmacokinetics (PK) of arbekacin in burn patients using a population–PK approach. Therapeutic drug monitoring data consisting of 126 plasma concentrations (including 17 values that were below the quantitation limit) from 47 burn patients were retrospectively analyzed using a mixed effect method ( NONMEM , ver. 6.0). Covariates, such as burn index, age, sex, among others, were tested on the basic one-compartment model. In the basic model, positive correlations of body weight (WT) and creatinine clearance (CLcr) on total clearance (CL) and volume of distributions (V) were assumed. In the final model, V increased with burn index (BI). The final model was: ; . Between-subject variability in terms of CL and V were 35 and 39%, respectively. The CL of our burn patients was significantly greater than that reported in unburned patients, and V increased proportionally with increasing BI.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0031-6970
1432-1041
DOI:10.1007/s00228-008-0470-1